FDA 483 - Claremore Compounding Center, Inc. - January 24, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA Form 483 details observations from an inspection, citing multiple deficiencies in drug product manufacturing. The facility used a non-pharmaceutical grade component, specifically orange food color, in drug products such as hydrocodone/dextromethorphan 10mg/10mg capsules (Lot #95806, 12/10/19) and 5mg/5mg capsules (Lot #94010, 9/11/19).
A significant quality system issue is the absence of a written stability testing program to determine Beyond Use Dates (BUD)/expiration dates for drug products. Examples include Dry Skin Moisturizing (OTC) 5% - 1% Cream (Lot #95371, 11/20/19) assigned a 360-day BUD, and CCC Cold Max and CCC Cough PE suspensions (Lots #94404 and #94402, 10/1/19) assigned 180-day BUDs. Jungle Juice Liquid (Lots #92698, #93496, #94749) also received a 360-day BUD without a stability program.
Furthermore, the firm does not conduct routine potency testing for all drug products prior to release, failing to ensure conformance to final specifications and identity/strength of active ingredients. This
- Office
- Dallas District Office
- Person
ID · 1528fd5a-1bdc-46e9-91a6-70a3cd2b5073
Full citation text and observation details available on the Dashboard.